Seres Therapeutics Inc [NASDAQ: MCRB] closed the trading session at $1.30 on 11/03/23. The day’s price range saw the stock hit a low of $0.97, while the highest price level was $1.55. The company report on November 2, 2023 at 7:00 AM that Seres Therapeutics Reports Third Quarter 2023 Financial Results Including VOWST™ Net Sales of $7.6 Million.
Rapid growth of VOWST continues with more than 1,500 patient enrollment forms received since FDA approval.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
Announces strategic restructuring to focus resources and investment on continued VOWST growth, completion of SER-155 Phase 1b study, and supporting longer-term business sustainability.
The stocks have a year to date performance of -76.79 percent and weekly performance of -5.80 percent. The stock has been moved at -78.00 percent over the last six months. The stock has performed -37.95 percent around the most recent 30 days and changed -71.80 percent over the most recent 3-months.
If compared to the average trading volume of 2.77M shares, MCRB reached to a volume of 30965079 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Seres Therapeutics Inc [MCRB]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MCRB shares is $8.54 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MCRB stock is a recommendation set at 1.86. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Oppenheimer have made an estimate for Seres Therapeutics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on June 26, 2023.
The Average True Range (ATR) for Seres Therapeutics Inc is set at 0.25, with the Price to Sales ratio for MCRB stock in the period of the last 12 months amounting to 1.29. The Price to Book ratio for the last quarter was 7.36, with the Price to Cash per share for the same quarter was set at 1.78.
MCRB stock trade performance evaluation
Seres Therapeutics Inc [MCRB] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.80. With this latest performance, MCRB shares dropped by -37.95% in over the last four-week period, additionally sinking by -78.00% over the last 6 months – not to mention a drop of -84.13% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MCRB stock in for the last two-week period is set at 38.56, with the RSI for the last a single of trading hit 42.70, and the three-weeks RSI is set at 35.52 for Seres Therapeutics Inc [MCRB]. The present Moving Average for the last 50 days of trading for this stock 2.2855, while it was recorded at 1.3305 for the last single week of trading, and 4.4422 for the last 200 days.
Seres Therapeutics Inc [MCRB]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Seres Therapeutics Inc [MCRB] shares currently have an operating margin of -3443.97 and a Gross Margin at -66.29. Seres Therapeutics Inc’s Net Margin is presently recorded at -3509.50.
Return on Total Capital for MCRB is now -138.66, given the latest momentum, and Return on Invested Capital for the company is -145.68. Return on Equity for this stock declined to -351.62, with Return on Assets sitting at -71.10. When it comes to the capital structure of this company, Seres Therapeutics Inc [MCRB] has a Total Debt to Total Equity ratio set at 1,507.84. Additionally, MCRB Total Debt to Total Capital is recorded at 93.78, with Total Debt to Total Assets ending up at 46.62. Long-Term Debt to Equity for the company is recorded at 1,470.21, with the Long-Term Debt to Total Capital now at 91.44.
Reflecting on the efficiency of the workforce at the company, Seres Therapeutics Inc [MCRB] managed to generate an average of -$580,411 per employee.Seres Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.16 and a Current Ratio set at 3.23.
Seres Therapeutics Inc [MCRB]: Institutional Ownership
The top three institutional holders of MCRB stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2579%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $201.66 billion in MCRB stocks shares; and BERKSHIRE HATHAWAY INC, currently with $177.59 billion in MCRB stock with ownership which is approximately 5.7994%.
